A 1-year pilot study of intralymphatic injections of GAD-alum in individuals with latent autoimmune diabetes in adults (LADA) with signs of high immunity: No safety concerns and resemblance to juvenile type 1 diabetes

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: onr:"swepub:oai:DiVA.org:liu-197486" > A 1-year pilot stud...

1 of 1
Previous record
Next record
To hitlist

Details
MARC

Hals, Ingrid K.Norwegian Univ Sci & Technol NTNU, Norway; Trondheim Reg & Univ Hosp, Norway; Nord Trondelag Hosp Trust, Norway (author)

A 1-year pilot study of intralymphatic injections of GAD-alum in individuals with latent autoimmune diabetes in adults (LADA) with signs of high immunity: No safety concerns and resemblance to juvenile type 1 diabetes

Article/chapterEnglish2023

Publisher, publication year, extent ...

WILEY,2023
electronicrdacarrier

Numbers

LIBRIS-ID:oai:DiVA.org:liu-197486
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-197486URI
https://doi.org/10.1111/dom.15239DOI
http://kipublications.ki.se/Default.aspx?queryparsed=id:153532928URI

Supplementary language notes

Language:English
Summary in:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:ref swepub-contenttype
Subject category:art swepub-publicationtype

Notes

Funding Agencies|St Olavs hospital, Trondheim university hospital (Trondheim, Norway); Central Norway Regional Health Authority (Trondheim,Norway); Norwegian Diabetes Association(Oslo, Norway); Central Norway Regional Health Authority (Trondheim, Norway); Norwegian Diabetes Association (Oslo,Norway); St Olavs Hospital, Trondheim University Hospital(Trondheim, Norway)
Aims: To test, for the first time in latent autoimmune diabetes in adults (LADA), the effects of autoantigen-specific immunotherapy by intralymphatic administration of aluminium-formulated recombinant human glutamic acid decarboxylase 65 (GAD-alum); specifically, to test if this treatment is safe, to test whether it induces a strong immunological response akin to a similar protocol in type 1 diabetes and to look for associations with preserved beta-cell function. Materials and Methods: Three GAD-alum injections, 4 mu g each, were administered 1 month apart into an inguinal lymph node in 14 people with newly diagnosed LADA (age 30-62 years) presenting with high levels of antibodies against glutamic acid decarboxylase (GADA). Adverse effects, immunological variables and beta-cell function were monitored, with detailed measurements at 5 and 12 months from baseline. Results: Clinical adverse effects were minor and transient and measured laboratory variables were unaffected. All participants completed the study. Treatment raised levels of GADA, elicited strong effects on reactivity of peripheral blood mononuclear cells to GAD and raised cytokine/chemokine levels. Beta-cell function appeared stable preferentially in the seven participants carrying human leukocyte antigen (HLA) haplotypes DR3DQ2, as assessed by C-peptide glucagon tests (P < 0.05 vs. seven non-carriers). Conclusion: Intralymphatic treatment with GAD-alum in LADA is without clinical or other safety concerns over a 12-month period. As in a similar protocol used in type 1 diabetes, treatment exerts a strong immunological impact and is compatible with protection of beta-cell function preferentially in HLA-DR3DQ2 LADA patients. These findings pave the way for a randomized controlled trial in this important subgroup of LADA patients.

Subject headings and genre

MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Endokrinologi och diabetes hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine Endocrinology and Diabetes hsv//eng
beta-cell function; clinical trial; drug development; insulin secretion; phase I-II study; type 1 diabetes

Added entries (persons, corporate bodies, meetings, titles ...)

Balasuriya, ChandimaTrondheim Reg & Univ Hosp, Norway (author)
Casas, RosauraLinköpings universitet,Avdelningen för barns och kvinnors hälsa,Medicinska fakulteten(Swepub:liu)rosca56 (author)
Ludvigsson, JohnnyLinköpings universitet,Avdelningen för barns och kvinnors hälsa,Medicinska fakulteten,Region Östergötland, H.K.H. Kronprinsessan Victorias barn- och ungdomssjukhus(Swepub:liu)johlu29 (author)
Bjorklund, AnneliKarolinska Inst, Sweden; Acad Specialist Ctr, Sweden (author)
Grill, ValdemarNorwegian Univ Sci & Technol NTNU, Norway (author)
Norwegian Univ Sci & Technol NTNU, Norway; Trondheim Reg & Univ Hosp, Norway; Nord Trondelag Hosp Trust, NorwayTrondheim Reg & Univ Hosp, Norway (creator_code:org_t)

Related titles

In:Diabetes, obesity and metabolism: WILEY25:11, s. 3400-34091462-89021463-1326

Internet link

Find in a library

Diabetes, obesity and metabolism (Search for host publication in LIBRIS)

To the university's database

1 of 1
Previous record
Next record
To hitlist

Find more in SwePub

By the author/editor: Hals, Ingrid K.; Balasuriya, Chan ...; Casas, Rosaura; Ludvigsson, John ...; Bjorklund, Annel ...; Grill, Valdemar

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Endocrinology an ...

Articles in the publication: Diabetes, obesit ...

By the university: Linköping University; Karolinska Institutet

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se